학술논문
Randomized phase III study of daratumumab versus bortezomib plus daratumumab as maintenance therapy after D-MPB for transplant-ineligible patients with untreated multiple myeloma (JCOG1911, B-DASH study).
Document Type
Article
Author
Source
Japanese Journal of Clinical Oncology; Apr2023, Vol. 53 Issue 4, p349-354, 6p
Subject
Language
ISSN
03682811